Rivaroxaban
Brand name: Xarelto
Rank #5 of 500 drugs by total cost
$2.45B
Total Cost
2,628,123
Total Claims
$2.45B
Total Cost
59,146
Prescribers
$934
Cost per Claim
397,398
Beneficiaries
4,585,380
30-Day Fills
$41K
Avg Cost/Provider
44
Avg Claims/Provider
About Rivaroxaban
Rivaroxaban (sold as Xarelto) was prescribed 2,628,123 times by 59,146 Medicare Part D providers in 2023, costing the program $2.45B. At $934 per claim, this is a high-cost medication.
💰 This drug alone accounts for 0.9% of all Medicare Part D drug spending.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 2 | Semaglutide (Ozempic) | $4.30B | 3,193,643 |
| 3 | Empagliflozin (Jardiance) | $3.58B | 3,334,784 |
| 4 | Dulaglutide (Trulicity) | $2.99B | 2,175,100 |
| 5 | Rivaroxaban (Xarelto) | $2.45B | 2,628,123 |
| 6 | Adalimumab (Humira(Cf) Pen) | $2.17B | 240,925 |
| 7 | Lenalidomide (Revlimid) | $2.15B | 130,834 |
| 8 | Insulin Glargine,hum.Rec.Anlog (Lantus Solostar) | $1.94B | 3,118,259 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology